Matching-adjusted indirect comparison of zanubrutinib and real-world chemotherapy, rituximab and chemoimmunotherapy in relapsed or refractory marginal zone lymphoma
Matching-adjusted indirekter Vergleich von Zanubrutinib und Real-World-Chemotherapie, Rituximab sowie Chemoimmuntherapie bei rezidiviertem oder refraktärem Marginalzonenlymphom
Journal of Comparative Effectiveness Research · 2026-11 · 15 (11)
DOI: 10.57264/cer-2026-0132 ↗Auf einen Blick
In einem unanchored matching-adjusted indirect comparison war Zanubrutinib mit längerem progressionsfreiem Überleben und Gesamtüberleben verbunden als Chemotherapie, Rituximab oder Chemoimmuntherapie.
Fragestellung
Wie wirkt Zanubrutinib im Vergleich zu Chemotherapie, Rituximab oder rituximabbasierter Chemoimmuntherapie bei rezidiviertem oder refraktärem Marginalzonenlymphom?
Methode
Unanchored matching-adjusted indirect comparison mit gepoolten Patient:innendaten aus Zanubrutinib-Studien und Registerdaten; Auswertung mit logistischer Propensity-Score-Anpassung und Cox-Modellen.
Ergebnisse
86 evaluierbare Patient:innen aus Zanubrutinib-Studien und 90 Patient:innen aus dem Register; effektive Stichprobe nach Matching 38. Gegenüber Chemotherapie, Rituximab oder CIT: PFS HR 0,30 (95 %-KI 0,15–0,63; p=0,001), OS HR 0,23 (95 %-KI 0,10–0,50; p<0,001).
Schlussfolgerung der Autor:innen
Die Modellierung mit klinischen Studiendaten und Real-World-Daten legt nahe, dass Zanubrutinib mit längerem PFS und OS verbunden war als Chemotherapie, Rituximab oder CIT.
Kernaussagen
- Zanubrutinib zeigte längeres PFS als Vergleichstherapien
- Zanubrutinib zeigte längeres OS als Vergleichstherapien
- Effektive Stichprobe nach Matching: 38
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Vergleichsstudie in der Zeitschrift Journal of Comparative Effectiveness Research, 2026-11. Verfasst von Renata Walewska und 8 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Care, University Hospitals Dorset, Bournemouth, UK. Hauptthemen laut MEDLINE: Rituximab, Lymphoma, B-Cell, Marginal Zone, Pyrimidines, Antineoplastic Agents. Die Arbeit nennt 25 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Aim
Traditional management of relapsed or refractory (R/R) marginal zone lymphoma (MZL) comprises chemotherapy, rituximab or rituximab-based chemoimmunotherapy (CIT). Zanubrutinib, a Bruton tyrosine kinase inhibitor, has shown high overall response rates and durable responses across MZL subtypes in two Phase II, single-arm trials. As no head-to-head randomized study exists, an unanchored matching-adjusted indirect comparison was performed to estimate the relative efficacy of zanubrutinib versus traditional agents. Materials & methods: Pooled patient-level data for 86 evaluable patients from zanubrutinib trials were compared with aggregate-level data from 90 patients treated with chemotherapy, rituximab or CIT in the Haematological Malignancy Research Network registry. Logistic propensity score models were used to match the populations for key characteristics. Progression-free survival (PFS) and overall survival (OS) associated with each treatment were estimated from Cox models. Since patients receiving chemotherapy generally have less favorable outcomes, a sensitivity analysis comparing zanubrutinib against CIT or rituximab alone was performed. Leave-one-out analyses were conducted where one covariate at a time was omitted to explore its impact on the results.
Results
The effective sample size for zanubrutinib after matching was 38. Compared with chemotherapy, rituximab or CIT, zanubrutinib significantly increased PFS (hazard ratio [HR]: 0.30 [95% CI: 0.15–0.63]; p = 0.001) and OS (HR: 0.23 [95% CI: 0.10–0.50]; p < 0.001) in patients with R/R MZL. Findings were consistent across leave-one-out analyses and when excluding patients who received chemotherapy only.
Conclusion
Modeling using clinical trial and real-world data from an unanchored matching-adjusted indirect comparison suggests that zanubrutinib was associated with longer PFS and OS compared with chemotherapy, rituximab or CIT in patients with R/R MZL.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cancer Care, University Hospitals Dorset, Bournemouth, UK.
- BeOne Medicines Ltd., San Carlos, CA 94070, USA.
- Precision AQ, London, UK.
- Precision AQ, Oakland, CA 94612, USA.
- BeOne Medicines Ltd., Basel, Switzerland.
- BeOne Medicines Ltd., London, UK.
ORCID-Profile: Renata Walewska
Zitieren
APA
Walewska, R., Wang, K., Smare, C., Zhang, I., Mohseninejad, L., Mardiguian, S., Keeping, S., Linton, K. M., & Walter, H. S. (2026). Matching-adjusted indirect comparison of zanubrutinib and real-world chemotherapy, rituximab and chemoimmunotherapy in relapsed or refractory marginal zone lymphoma. Journal of Comparative Effectiveness Research, 15(11). https://doi.org/10.57264/cer-2026-0132
Vancouver
Walewska R, Wang K, Smare C, Zhang I, Mohseninejad L, Mardiguian S, et al. Matching-adjusted indirect comparison of zanubrutinib and real-world chemotherapy, rituximab and chemoimmunotherapy in relapsed or refractory marginal zone lymphoma. Journal of Comparative Effectiveness Research. 2026;15(11). doi:10.57264/cer-2026-0132
BibTeX
@article{Walewska2026,
author = {Walewska, Renata and Wang, Kaijun and Smare, Caitlin and Zhang, Ina and Mohseninejad, Leyla and Mardiguian, Silvy and Keeping, Sam and Linton, Kim M and Walter, Harriet S},
title = {Matching-adjusted indirect comparison of zanubrutinib and real-world chemotherapy, rituximab and chemoimmunotherapy in relapsed or refractory marginal zone lymphoma},
journal = {Journal of Comparative Effectiveness Research},
year = {2026},
volume = {15},
number = {11},
doi = {10.57264/cer-2026-0132}
}
EUVIMED